This trial will test how safe and effective GEN1042 is in treating patients with metastatic or locally advanced solid tumors.
8 Primary · 19 Secondary · Reporting Duration: From the start of study treatment until death due to any cause, assessed up to 36 months after the last subject's first treatment in the trial.
647 Total Participants · 12 Treatment Groups
Primary Treatment: GEN1042 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: